dihydroergotamine
NDA- Indications
- episodic migraine, migraine with aura, migraine without aura
Company intelligence / Profile preview
Satsuma Pharmaceuticals
Durham, North Carolina, USsatsumarx.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
FDA-approved Atzumi™ (formerly STS101) in April2025 as first DHE nasal powder using SMART Platform. Demonstrated rapid/sustained DHE concentrations in clinical trials across >10,000 treated migraine attacks.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
SNBL(device technology licensor)
Beyond the preview
Go deeper on Satsuma Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Satsuma Pharmaceuticals.